Outcomes in COVID-19 amantadine studies

0 0.5 1 1.5+ All studies -19% 3 527 Improvement, Studies, Patients Relative Risk Mortality -0% 2 285 ICU admission 18% 1 186 Hospitalization -67% 1 242 Recovery 5% 2 341 RCTs -19% 3 527 RCT mortality -0% 2 285 Late -19% 3 527 Amantadine for COVID-19 c19early.org December 2025 Favorsamantadine Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Barczyk (DB RCT) -13% 1.13 [0.40-3.23] death 95 (n) 91 (n) Improvement, RR [CI] Treatment Control Rejdak (DB RCT) 66% 0.34 [0.01-8.04] death 0/49 1/50 ACT Weis (DB RCT) -67% 1.67 [0.41-6.82] hosp. 5/121 3/121 Tau​2 = 0.00, I​2 = 0.0%, p = 0.69 Late treatment -19% 1.19 [0.53-2.67] 5/265 4/262 19% higher risk All studies -19% 1.19 [0.53-2.67] 5/265 4/262 19% higher risk 3 amantadine COVID-19 studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.69 Effect extraction pre-specified(most serious outcome) Favors amantadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Barczyk (DB RCT) -13% 1.13 [0.40-3.23] 95 (n) 91 (n) Improvement, RR [CI] Treatment Control Rejdak (DB RCT) 66% 0.34 [0.01-8.04] 0/49 1/50 Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Late treatment -0% 1.00 [0.37-2.71] 0/144 1/141 0% higher risk All studies -0% 1.00 [0.37-2.71] 0/144 1/141 0% higher risk 2 amantadine COVID-19 mortality results c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Favors amantadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Barczyk (DB RCT) 18% 0.82 [0.26-2.55] 95 (n) 91 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.75 Late treatment 18% 0.82 [0.26-2.55] 95 (n) 91 (n) 18% lower risk All studies 18% 0.82 [0.26-2.55] 95 (n) 91 (n) 18% lower risk 1 amantadine COVID-19 ICU result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.75 Favors amantadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACT Weis (DB RCT) -67% 1.67 [0.41-6.82] hosp. 5/121 3/121 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.49 Late treatment -67% 1.67 [0.41-6.82] 5/121 3/121 67% higher risk All studies -67% 1.67 [0.41-6.82] 5/121 3/121 67% higher risk 1 amantadine COVID-19 hospitalization result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.49 Favors amantadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Barczyk (DB RCT) -13% 1.13 [0.40-3.23] death 95 (n) 91 (n) Improvement, RR [CI] Treatment Control Rejdak (DB RCT) 66% 0.34 [0.01-8.04] death 0/49 1/50 ACT Weis (DB RCT) -67% 1.67 [0.41-6.82] hosp. 5/121 3/121 Tau​2 = 0.00, I​2 = 0.0%, p = 0.69 Late treatment -19% 1.19 [0.53-2.67] 5/265 4/262 19% higher risk All studies -19% 1.19 [0.53-2.67] 5/265 4/262 19% higher risk 3 amantadine COVID-19 serious outcomes c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.69 Effect extraction pre-specified(most serious outcome) Favors amantadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rejdak (DB RCT) 39% 0.61 [0.40-0.94] no recov. 18/49 30/50 Improvement, RR [CI] Treatment Control ACT Weis (DB RCT) -48% 1.48 [0.95-2.30] no recov. 37/121 25/121 Tau​2 = 0.34, I​2 = 87.3%, p = 0.92 Late treatment 5% 0.95 [0.40-2.26] 55/170 55/171 5% lower risk All studies 5% 0.95 [0.40-2.26] 55/170 55/171 5% lower risk 2 amantadine COVID-19 recovery results c19early.org December 2025 Tau​2 = 0.34, I​2 = 87.3%, p = 0.92 Favors amantadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Barczyk (DB RCT) -13% 1.13 [0.40-3.23] death 95 (n) 91 (n) Improvement, RR [CI] Treatment Control Rejdak (DB RCT) 66% 0.34 [0.01-8.04] death 0/49 1/50 ACT Weis (DB RCT) -67% 1.67 [0.41-6.82] hosp. 5/121 3/121 Tau​2 = 0.00, I​2 = 0.0%, p = 0.69 Late treatment -19% 1.19 [0.53-2.67] 5/265 4/262 19% higher risk All studies -19% 1.19 [0.53-2.67] 5/265 4/262 19% higher risk 3 amantadine COVID-19 Randomized Controlled Trials c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.69 Effect extraction pre-specified(most serious outcome) Favors amantadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Barczyk (DB RCT) -13% 1.13 [0.40-3.23] 95 (n) 91 (n) Improvement, RR [CI] Treatment Control Rejdak (DB RCT) 66% 0.34 [0.01-8.04] 0/49 1/50 Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Late treatment -0% 1.00 [0.37-2.71] 0/144 1/141 0% higher risk All studies -0% 1.00 [0.37-2.71] 0/144 1/141 0% higher risk 2 amantadine COVID-19 RCT mortality results c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Favors amantadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Barczyk (DB RCT) -13% 1.13 [0.40-3.23] death 95 (n) 91 (n) Improvement, RR [CI] Treatment Control Rejdak (DB RCT) 66% 0.34 [0.01-8.04] death 0/49 1/50 ACT Weis (DB RCT) -67% 1.67 [0.41-6.82] hosp. 5/121 3/121 Tau​2 = 0.00, I​2 = 0.0%, p = 0.69 Late treatment -19% 1.19 [0.53-2.67] 5/265 4/262 19% higher risk All studies -19% 1.19 [0.53-2.67] 5/265 4/262 19% higher risk 3 amantadine COVID-19 peer reviewed studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.69 Effect extraction pre-specified(most serious outcome) Favors amantadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Barczyk (DB RCT) -13% 1.13 [0.40-3.23] death 95 (n) 91 (n) Improvement, RR [CI] Treatment Control Barczyk (DB RCT) 18% 0.82 [0.26-2.55] ICU 95 (n) 91 (n) Rejdak (DB RCT) 66% 0.34 [0.01-8.04] death 0/49 1/50 Rejdak (DB RCT) 39% 0.61 [0.40-0.94] no recov. 18/49 30/50 Rejdak (DB RCT) 89% 0.11 [0.01-2.03] progression 0/49 4/50 Rejdak (DB RCT) 23% 0.77 [0.18-3.24] progression 3/49 4/50 ACT Weis (DB RCT) -67% 1.67 [0.41-6.82] hosp. 5/121 3/121 ACT Weis (DB RCT) -48% 1.48 [0.95-2.30] no recov. 37/121 25/121 Amantadine COVID-19 outcomes c19early.org December 2025 Favors amantadine Favors control